Shop Now Contact

Anti-Human EGFR (Matuzumab Biosimilar)

Cat # Size Price Quantity
5036011 mg$250
5036025 mg$650
50360320 mg$2000

  Bulk/Custom

Product Details

CloneMatuzumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionMatuzumab Biosimilar, EGFR Monoclonal Antibody
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman EGFR
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsErbB1, HER1
Target NameEGFR, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, HER1
Antibody TypeRecombinant
Research AreasCancer Marker, Epithelial cells
See All FormatsClone Matuzumab

Background Information

Matuzumab is a humanized monoclonal antibody belonging to the immunoglobulin G1 (IgG1) subclass and is specifically engineered to target the human epidermal growth factor receptor (EGFR), also known as ErbB1 or HER1. Structurally, Matuzumab is a glycoprotein with a molecular weight of approximately 150 kilodaltons (kDa), composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds, forming the classical Y-shaped structure characteristic of IgG antibodies. Each heavy chain contains one variable (VH) domain and three constant (CH1-CH3) domains, while each light chain contains one variable (VL) and one constant (CL) domain. The antibody is produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells to ensure accurate folding and glycosylation.

The variable regions of Matuzumab, particularly the complementarity-determining regions (CDRs), are derived from murine antibodies and confer high specificity and affinity for the extracellular domain III of EGFR. This epitope corresponds to a key region responsible for ligand binding to signaling molecules such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α). By binding to this site, Matuzumab sterically hinders ligand attachment and subsequent receptor dimerization, thereby blocking activation of the receptor’s intracellular tyrosine kinase domain. This inhibition prevents autophosphorylation of key tyrosine residues and halts downstream signaling through pathways including RAS-RAF-MEK-ERK and PI3K-AKT, which regulate cell proliferation, differentiation, and survival in experimental cell models.

The Fc (fragment crystallizable) domain of the IgG1 subclass contributes to Matuzumab’s structural stability and prolongs its half-life through neonatal Fc receptor (FcRn)–mediated recycling. It also allows limited engagement with Fc gamma receptors (FcγRs), enabling potential immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) in vitro.

Data Sheets

Anti-Human EGFR (Matuzumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Anti-Human EGFR Antibody, Clone 528

Anti-Human EGFR (Cetuximab Biosimilar), Clone Cetuximab

Anti-Human EGFR (Nimotuzumab Biosimilar), Clone Nimotuzumab

Anti-Human EGFR (Panitumumab Biosimilar), Clone Panitumumab

Biotin Anti-Human EGFR Antibody, Clone 528

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.